Trial
NCT00458159
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Celgene
Collaborators
—
Condition
Myelodysplastic Syndrome
Intervention
CC-11006
Why stopped
The compound has a benign safety profile with short-term use, clinically sig efficacy responses have not been demonstrated, or if so, have not been sustained.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-13